@article {Abid92, author = {Muhammad Bilal Abid}, title = {Could the menagerie of the gut microbiome really cure cancer? Hope or hype}, volume = {7}, number = {1}, elocation-id = {92}, year = {2019}, doi = {10.1186/s40425-019-0561-9}, publisher = {BMJ Specialist Journals}, abstract = {The investigational scale of the gut microbiome is expanding rapidly. In 2018, the intersection of gut microbiota and immuno-oncology received much attention. While the impact of gut microbiota on the immune system was already established, the year received an exponential expansion of microbiome{\textquoteright}s role in the immunotherapy setting. The microbiome research pipeline is ripe for large-scale, prospective trials. Working knowledge of immune-based cancer treatments, heterogeneity in their responses and resistance mechanisms, relevant immunological and microbiological pathways and potential for gut microbiome in enhancing the responses, is critical.Abbreviations:ACTAdoptive T-cell transferAlloHCTAllogeneic hematopoietic stem cell transplantationCAR T-cellsChimeric antigen receptor T-cellsCRISPRClustered regularly interspaced short palindromic repeatsCYCCyclophosphamideDCDendritic cellICIImmune checkpoint inhibitionmLNMesenteric lymph nodesSCFAShort chain fatty acidTMETumor microenvironmentTregsRegulatory T-cells}, URL = {https://jitc.bmj.com/content/7/1/92}, eprint = {https://jitc.bmj.com/content/7/1/92.full.pdf}, journal = {Journal for ImmunoTherapy of Cancer} }